Although atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) patients, the relationship between genetic variation and AF has been poorly defined. Characterizing genetic subtypes of HCM and their associations with AF may help to improve personalized medical care. We aimed to investigate the link between sarcomeric gene variation and incident AF in HCM patients.
H
ypertrophic cardiomyopathy (HCM) affects ≈1 of 500 people in United States 1 and is commonly complicated by atrial and ventricular arrhythmias. Over 1400 rare variants in at least 8 sarcomererelated genes are linked to HCM, with variations in the MYH7 and MYBPC3 genes most common. 2 Atrial fibrillation (AF) is the most prevalent arrhythmia, affecting ≈15% to 25% of patients with HCM in cross-sectional studies. [3] [4] [5] Those with HCM who develop AF have lower exercise tolerance 6 and often experience clinical deterioration with symptoms and complications that become challenging to manage. In addition, patients with HCM who develop AF are at a >3-fold higher risk of death compared with those without AF. 7 Why some patients with HCM develop AF and others do not is incompletely understood. Several well-established risk factors for AF, primarily age and left atrial (LA) size, have been correlated with AF in those with HCM. 4, 8, 9 However, there are additional pathophysiologic processes that may account for the increased susceptibility to AF. Patients with HCM have higher rates of mitral valvular abnormalities, 10 which may result in increased atrial stretch. Dysregulation of calcium handling by sarcomeric gene mutations may also help explain enhanced arrhythmogenicity. 11 Considering the possible diverse mechanisms of AF in HCM, exploring a more sophisticated approach to clinical management using subtypes of HCM to develop precision care is warranted. Pertinent information encompassing a wide array of demographic, hemodynamic, structural, and genetic data may help characterize more finely which HCM patients are at risk of developing AF, thus providing a first step to delivering precision medicine 12 in HCM. This has become possible because of wide implementation of genetic testing provided to HCM patients and their families 13 as well as collaboration between clinical centers to gather a large volume database. 14 Although MYH7 expression is more robust in the ventricle, 15 there have been several studies showing an association between the switch of the myosin heavy chain protein isoforms in the atria and development of AF. [16] [17] [18] In addition, genetic variation in MYH7 is associated with higher levels of propeptide of type I procollagen, a marker of collagen synthesis, in early stages of HCM, 19 suggesting that fibrosis could mediate a link between MYH7 and AF. In this study, we hypothesized that pathogenic variation in MYH7 could be linked to AF in HCM. The objective of this study was to investigate the incidence of AF in a large cohort of genotyped HCM patients and to test whether those with pathogenic variation in MYH7 would be more likely to develop AF compared with those with pathogenic variation in other sarcomeric genes.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure as there is ongoing analysis with this cohort.
Patient Population
The Sarcomeric Human Cardiomyopathy Registry (SHaRe) is a multinational registry of 8 referral centers providing specialized care in HCM patients. 20 Patients with HCM received a clinical diagnosis based on the presence of unexplained left ventricular (LV) hypertrophy, integrating familial or sporadic occurrence and genotype and ≥1 echocardiographic assessment of the LV wall thickness at the SHaRe site. The study conforms to the principles of the Helsinki declaration and the local institutional review boards approved the study protocol. All study participants gave informed consents.
HCM patients in the SHaRe cohort, as of March 2017, who underwent genotyping and had at least 1 variant in the MYH7, MYBPC3, or thin filament (TNNI3, TNNT2, TPM1 or ACTC1) genes, were included in the primary analysis. Patients with baseline AF and those without adequate clinical follow-up, that is, only one clinic encounter at the SHaRe site, were excluded. Patients with mutations in ≥2 genes or with mutations in the MYL2 or MYL3 were excluded from the primary analysis because of the small number of patients ( Figure 1 ). Demographic information and medical histories were obtained via review of medical records and harmonized across all contributing sites into a central database.
Echocardiographic Evaluation
The first resting echocardiographic examination after the initial encounter at the SHaRe site was analyzed. All
WHAT IS NEW?
• Hypertrophic cardiomyopathy (HCM) patients with pathogenic variation in the MYH7 gene suffer from higher rates of incident atrial fibrillation (AF) than those with variation in other sarcomeric genes.
• Patients with genetic variation in the hot spots of the MYH7 gene that are more frequently associated with HCM than other sites of the MYH7 gene may be more prone to develop AF in the future.
• Factors other than the sarcomeric gene variation, such as age, left atrial diameter, maximal left ventricle wall thickness, and the left ventricular outflow tract pressure gradient, independently contribute to the development of AF in HCM patients.
WHAT ARE THE CLINICAL IMPLICATIONS?
• An HCM patient with pathogenic variation in the MYH7 gene may be at greater risk of AF and may benefit from more aggressive surveillance.
• Further studies on how medical treatment of HCM in specific genotypes differentially affects the rates of AF and how it is associated with AF-related comorbidities are warranted.
echocardiographic measurements were made according to standardized guidelines. 21 
Study End Point
Incident AF was defined as the first documentation of a new clinical diagnosis in the patient's medical record. A diagnosis of AF was based on the clinical interpretation of at least 1 electrocardiographically documented episode of AF. The incident AF episode was assessed individually at each SHaRe investigation site and captured via quarterly uploads from site databases. Postoperative AF was not included as the study end point.
Genetic Testing
Variants were identified through genetic testing performed during routine clinical care of patients at the SHaRe centers from 1992 to 2014 using different platforms available over time. All clinical genetic analyses encompassed at least 8 sarcomeric genes of interest: myosin binding protein C (MYBPC3), β-myosin heavy chain (MYH7), essential and regulatory myosin light chains (MYL2, MYL3), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), α-tropomyosin (TPM1), and actin (ACTC1). The pathogenicity of each variant was classified by the clinical team at each SHaRe site and also systematically reassessed with the most updated information by a subgroup of investigators in the SHaRe to harmonize the classifications across each site. Variants were classified as likely pathogenic or pathogenic (LP/P) using data including but not restricted to conservation, segregation, review of the literature, and the public databases such as ClinVar and the prevalence of each variant in control populations.
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Classification of Genetic Variation in the MYH7 S1 Domain Surface Region
With a spatial scan analytic model developed in our group, 14 we identified a specific surface region on the head region of β-myosin heavy chain protein that more frequently harbored HCM-associated genetic variants ( Table I in the Data Supplement). We used the 3-dimensional structure of the MYH7 S1 domain based on a computational model of the human β-myosin heavy chain protein before and after the myosin power stroke. This model aimed to identify specific hot spots or regions on the surface of S1 domain enriched for HCM-causative variants (HCM-enriched surface region) compared with the population-scale genetic variation. These HCM-associated genetic variation sites are associated with earlier HCM onset than those with variants elsewhere in the MYH7 S1 domain. 14 We further classified the patients with variation in the MYH7 S1 domain into 2 groups, those with variation in the HCM-enriched surface region versus those with variation in the non-HCM-enriched surface region. Two models of the β-myosin heavy chain domain were analyzed because of the dynamic nature of the myosin head according to the cardiac contraction, before and after the myosin power stroke (hereby named as the precontraction phase and the postcontraction phase). Those with genetic variation in the MYH7 S1 domain but not on the surface region were not included in this analysis.
Statistical Analysis
Demographic features were compared between the 3 groups of patients with either MYH7, MYBPC3, or thin filament gene mutation by ANOVA or by χ 2 test. All post hoc pairwise comparison was done with Tukey's Honestly Significant Difference post hoc test. Survival free from new-onset AF was depicted by Kaplan-Meier plots, and a log-rank test was performed to measure differences. Survival analyses were performed with the time from first clinical encounter at SHaRe site (index encounter). Statistical significance of the post hoc pairwise comparison between the survival curves was determined with Bonferroni correction. Independent predictors of incident AF were assessed using multivariate Cox hazard regression analysis. Covariates in the Cox regression model were selected based on clinical relevance. Analyses were done with SPSS 21.0 (SPSS Inc, Chicago, IL), and a P <0.05 was considered statistically significant. The P values are not adjusted for multiple comparisons.
RESULTS
Baseline Characteristics
Of the 6082 patients enrolled in SHaRe, 3618 underwent genotyping and 2072 had at least 1 variant in a sarcomeric gene. Of these, 1516 patients aged ≥18 years had at least 1 LP/P variant in a sarcomeric gene. Among these 1516 HCM patients, there were 153 (9.7%) HCM patients with AF at baseline, 22 with variants in ≥2 genes, 31 with variants in the MYL2 or MYL3 genes, and 270 without adequate clinical follow-up who were excluded. Finally, there were 1040 patients with a single LP/P variant in either the MYH7 (n=296), MYBPC3 (n=659), or the thin filament genes (n=85) that remained for the primary analysis.
Baseline demographic and clinical characteristics are summarized in Table 1 . Patients with variants in the MYH7 or the thin filament genes tended to present for specialty care at a younger age than those with the MYBPC3 variant. There were significantly more probands in the MYH7 than the MYBPC3 group on post hoc analysis. There was no difference in the proportion of patients with implantable cardioverter-defibrillator or baseline septal reduction therapy between the 3 groups. However, the patients with genetic variation in the MYBPC3 gene tended to undergo septal reduction therapy more frequently during the follow-up at the SHaRe site (Table 1) .
Echocardiographic Evaluation
On echocardiography, the patients had on average a maximal LV wall thickness of 19.7 mm, a resting gradient of 23 mm Hg, and an LA diameter of 44.2 mm (Table 2 ). There was no significant difference in the LV end-diastolic dimension, LV wall thickness, nor the LA diameter between the 3 groups. However, the LV ejection fraction differed significantly between those with variants in MYH7, MYBPC3, and thin filament genes (66.8±8.9%, 63.4±8.4%, and 64.3±9.0%, respectively, P<0.001 by ANOVA). The degree of dynamic LV outflow tract obstruction measured by the peak LV outflow tract pressure gradient at rest was also significantly different in these 3 groups (27.4±28, 21.4±26.3, and 19.6±27.3 mm Hg, respectively, P=0.026 by ANOVA). 
Development of Incident AF in Patients With MYH7 Genetic Variation
During an average follow-up of 7.2 years, there were 198 cases of new-onset AF. On univariate analyses using Kaplan-Meier plots, there were significant differences in the incidence of new-onset AF between the 3 groups (log-rank P=0.001, Figure 2 ). In post hoc pairwise analyses, those with variation in the MYH7 gene had lower rates of AF-free survival compared with those with MYB-PC3 or thin filament gene variants (log-rank P=0.002 for comparison with MYBPC3; log-rank P=0.005 for comparison with thin filament genes). There was no difference in AF-free survival between the MYBPC3 group and the thin filament group (log-rank P=0.212). When the MYH7 and the MYBPC3 variants were combined into 1 thick filament mutation group, the difference in the rate of incident AF between the thick versus the thin filament group was not statistically significant (log-rank P=0.062).
Incidence of AF in Patients With Genetic Variation in the Surface Region of MYH7 S1 Domain
Focusing on those with variation in the MYH7 S1 domain, those with variation in the HCM-enriched surface region tended to present at younger age than those with variation in the non-HCM-enriched surface region at the precontraction model. However, there was no difference in the baseline characteristics between the 2 groups in the postcontraction model (Table II in the Data Supplement) . The comparison of echocardiography data between those with variation in the HCM-enriched surface region versus the non-HCM-enriched surface region at pre-and postcontraction model is also summarized.
In the subgroup of patients with variation in the MYH7 gene S1 domain, we tested whether the surface region enriched for HCM-associated variation 14 was more prone to AF development. Both at precontraction and at postcontraction model, ≈26% of the patients developed new-onset AF (42/158 for the precontraction model, 44/167 for the postcontraction model, Table II in the Data Supplement). The incidence of new-onset AF was higher in those with variation in the HCM-enriched surface region versus those with variation in the non-HCM-enriched surface region in the postcontraction phase (log-rank P=0.047, Figure 3A and 3B). This trend was not statistically significant in the precontraction phase ( Figure I in the Data Supplement).
Subgroup Analysis for Incident AF
We also wanted to analyze whether the AF-prone status in the MYH7 group is not because of the difference in the proportion of probands or of those who had occult HCM between each genotypes. A subgroup analysis with probands only demonstrated that those with the MYH7 variant were more likely to develop AF than those with the MYBPC3 or the thin filament gene variant (log-rank P=0.016; Figure 4A ). This was also true when the analysis was restricted to those with interventricular septal thickness >12 mm (log-rank P=0.009; Figure 4B ). We also analyzed whether genetic variation could affect AF development in patients with age ≤40 years on index encounter, those who would not be likely to develop AF because of age. Variation in The data are presented as mean±SD and analyzed for differences in the mean between the 3 groups using ANOVA. LA indicates left atrial; LV, left ventricular; and LVOT, left ventricular outflow tract. *P<0.05 for comparison between MYH7 vs MYBPC3 on post hoc analysis with Tukey procedure.
Figure 2. Atrial fibrillation (AF)-free survival by variation in either the
MYH7, MYBPC3, or the thin filament genes.
The log-rank test refers to the comparison of all 3 groups. The numbers below the Kaplan-Meier curve denote the number of patients at risk in each group. *P<0.05 for comparison versus the MYH7 group on post hoc analysis after Bonferroni correction.
the MYH7 gene was associated with lower rates of AFfree survival in this subgroup with age ≤40 years (logrank P=0.005; Figure 4C ). Further sensitivity analysis demonstrated that the patients with the MYH7 variant had lower rates of AF-free survival compared with those with LP/P variant in other sarcomeric genes grouped together, that is, those who had either LP/P variation in the MYBPC3, thin filament gene, MYL2, or MYL3 ( Figure IIA in the Data Supplement). The AF-free survival was also lower in the patients with the MYH7 variant compared with all others grouped together, including those with no LP/P sarcomeric variants and those who did not have variants detected on genotyping ( Figure IIB in the Data Supplement).
We also compared the AF incidence between the missense versus the nonsense variants in either the MYH7, MYBPC3, or the thin filament genes (n=1040) or only the MYBPC3 gene variants (n=659). The AF incidence was not different between the missense versus the nonsense variants in either population, suggesting that the effect of the genetic change is not as important as the affected gene itself.
Multivariate-Adjusted Predictors of Incident AF
We performed a multivariate Cox hazard regression analysis to demonstrate the association between MYH7 variation and development of AF using several covariates with clinical relevance (Table 3) . After adjusting for demographic covariates such as age at index encounter, proband status, and sex, rare variation in the MYH7 gene, compared with that in the MYBPC3 gene, was associated with a higher incidence of AF (hazard ratio [HR], 1.720; 95% CI, 1.269-2.332; P<0.001). As previously reported, 8 LA diameter, peak LV outflow tract pressure gradient at rest, and maximal LV wall thickness were also associated with higher rates of AF in our cohort. Variation in the MYH7 gene remained a significant predictor of incident AF when these echocardiographic variables were added to the multivariate model (HR, 1.724; 95% CI, 1.148-2.591; P=0.009). Thin filament gene variation was not associated with incident AF compared with the thick filament group nor the MYH7 group (data not shown). On sensitivity analysis after adding incident septal reduction therapy before AF as a covariate to the primary model, we still found that rare variation in the MYH7 gene, compared with that in the MYBPC3 gene, was associated with a higher incidence of AF (HR, 1.643; 95% CI, 1.210-2.232; P=0.001). In addition, variation in the HCM-enriched surface region of the MYH7 in the postcontraction model was associated with higher incidence of AF when adjusted for demographic covariates compared with non-HCM-enriched surface region (HR, 2.055; 95% CI, 1.085-3.894; P=0.027).
We also analyzed whether variation in the MYH7 gene was associated with incident AF in probands, in those with interventricular septal thickness >12 mm and in those with age ≤40 years at index encounter. Compared with variation in the MYBPC3 gene, variation in the MYH7 gene was a significant, independent predictor of incident AF in the multivariate Cox hazard regression analysis in each of these subgroups (HR, 1.661; 95% CI, 1.068-2.585; P=0.024 in probands only; HR, 1.765; 95% CI, 1.152-2.704; P=0.009 in those with interventricular septal thickness >12 mm; HR, 2.206; 95% CI, 1.119-4.348; P=0.022 in those with age ≤40 years at index encounter).
In addition, we evaluated the interaction between several baseline covariates and the association between the MYH7 gene variation and incident AF. The effect of variation in MYH7 was similar across the strata of age, proband, sex, LA diameter, and the maximal pressure gradient, with no significant interactions ( Figure 5 ). A, Kaplan-Meier plot of AF-free survival in the HCM-enriched surface region of the β-myosin heavy chain S1 domain compared with the non-HCM-enriched surface regions in the postcontraction phase. The numbers below the Kaplan-Meier curve denote the number of patients at risk in each group. B, Three-dimensional structure of the S1 domain of β-myosin heavy chain in the postcontraction phase, shown in orthogonal projections and its association with incident AF. The residue colors are beige, HCM-enriched surface region; light gray, non-HCM-enriched residues considered to be on the surface of the S1 domain; dark gray, residues considered not to be on the surface of the S1 domain; red, residues associated with incident AF; and blue, residues not associated with incident AF. The residues with both incident AF and without were colored as red.
DISCUSSION
In this analysis of a large multinational registry of HCM patients, we report that LP/P variation in MYH7 is associated with an increased rate of incident AF, independent of established risk factors of AF such as age, LA enlargement, and also HCM-specific factors such as maximal LV wall thickness and peak LV outflow tract pressure gradient. The primary justification for studying incident AF and excluding baseline AF was to help establish the predictive value of genotype data in a clinical setting. To our knowledge, this is the largest study to demonstrate that LP/P variation in a specific sarcomeric gene is associated with incident AF in HCM patients. The findings of this study may provide further insights into the factors that contribute to higher incidence of AF in patients with HCM.
Although there have been efforts to define patient groups more prone to develop AF, 8 classifying HCM by subtypes could help deliver more precise prognostication. Rather than a one-size-fits-all approach, a better characterization of those at risk is needed as has been defined by the precision medicine initiative.
12 Defining genetic subtypes of HCM and furthermore, defining certain regions within each gene, that are more AFprone is an important step toward a precision model in the management of AF.
We aimed to predict AF in patients with HCM based on the patients' genetic context. We carefully tested the validity of our hypothesis by integrating a range of demographic, hemodynamic, structural, and genetic data in a large HCM cohort. Given high stroke rates 3 and other clinical consequences of AF in HCM, 7 our analysis could provide clinicians with markers of AF susceptibility that can ultimately lead to more focused aggressive surveillance and, possibly, early intervention. This study also demonstrates the power of using comprehensive, harmonized clinical data gathered from multiple centers to create a large but carefully genotyped cohort of patients with HCM. This allowed us to establish a clear association between rare genetic variation in MYH7 and AF, which had been a challenging task previously. 23 In a previously published family of 24 individuals with HCM because of the Arg663His MYH7 missense variant, affected family members had a higher rate of AF compared with ungenotyped HCM patients. 24 Although it focused on a single family with 1 MYH7 variant and did not include adjustment for clinical and echocardiographic risk factors of AF, it was consistent with our findings. In a Brazilian cohort of HCM, the variation in the MYH7 gene was found more commonly than the MYBPC3 in patients with AF. 25 However, it was underpowered to show whether this was because of genetic variation or the effect of structural/ hemodynamic factors or a mixture of both. In contrast, a prior single-center study found a lack of association between HCM genetic subtype and AF, 26 but by comparison, this analysis was of prevalent AF and performed in a much smaller cohort. The strengths of our study are that it is the largest genotyped HCM cohort study of incident AF, and importantly, it adjusted for structural and hemodynamic factors.
The reason for higher frequency of AF in HCM patients with MYH7 mutations is not yet clear. Variation in the MYH7 gene may cause more pervasive myocardial disease leading to worse heart function which itself could be associated with a higher rate of AF. Classical factors, such as age and LA size, known to be associated with AF in the general population are predictors of AF in HCM patients, 8 a finding replicated in our analysis also. In addition, although we do not have the diastolic function data available, the larger LA size in patients with MYH7 variation despite the younger age may be an indicator of increased LV diastolic pressure and worse diastolic dysfunction, a hallmark of HCM. 27 This is also reflected in our sensitivity analysis demonstrating that prior septal reduction therapy, which is associated with reduction of LA size, 28, 29 is associated with reduction of AF incidence (HR, 0.40; 95% CI, 0.24-0.66; P<0.001). However, we are the first to report that the association between AF and MYH7 was independent of these demographic and echocardiographic factors. Therefore, there may be a direct link between MYH7 and the incidence of AF that is independent of the hemodynamic effects, mediated by processes such as atrial fibrosis or extracellular matrix remodeling that should be investigated further.
Although exploratory, we suggest that a specific surface region of the β-myosin heavy chain S1 domain, that we previously identified as hot spots of HCM-associated genetic variation, 14 may be associated with higher incidence of AF. This region, which includes the myosin mesa and the converter domain of the β-myosin heavy chain, 30 is associated with younger age at diagnosis of HCM, 14 and after correction of age in our analysis, the genetic variation in the HCM-enriched surface region was a significant predictor of incident AF. Again, the combination of hemodynamic factors, especially the diastolic function reflected by LA size, as well as the 3-dimensional regional location of variation may serve as a marker of arrhythmogenic susceptibility. This is partially supported by previous data suggesting that the variant location in the myosin head may be a critical factor for impaired diastolic relaxation in HCM. 31 However, as the significance is borderline, further analysis with a larger population of HCM patients of regional variation in the MYH7 will be needed to validate this secondary analysis.
Although the thin filament genetic subtype, which has different features compared with those with variation in the thick filament genes, 32 had lower rates of incident AF compared with the MYH7 genetic subtype, the variation in the thin filament genes was not an independent predictor of incident AF. This is consistent with a previous report demonstrating that there was no difference in the new-onset AF incidence between the thick versus the thin filament group. 32 We now provide more supporting evidence with a longer follow-up duration and more events.
There are several limitations that should be considered. First, the proportion of patients with >1 clinical encounter in the MYH7 variants was higher than those with MYBPC3 variants, and therefore, the incidence AF may have been underestimated in the MYBPC3 variant population compared with the MYH7 group. Second, although it would have been more informative to adjust for additional potentially confounding risk factors for AF such as hypertension, obesity, and diabetes mellitus, these risk factors were not universally available. Although the association study of a single variant, rare or common, may be confounded by population stratification, comparisons of variation at the gene level are less likely be confounded by race and have been performed in previous meta-analyses. 33 Third, we do not have data on medications and considering that certain medications may retard the development of AF, 8 this may be a limitation of our study. However, this antiarrhythmic effect of the medication tends to fade away quite fast (1-3 years), 8 and given the progressive nature of AF development in HCM and the limited effect of medications, we think that the effect of medications would be minimal, if any. Last, how rare variation in sarcomeric genes affects the relationship between AF and stroke or thromboembolic events in HCM needs further study. On preliminary analyses, we did not find a statistically independent association between incident or prevalent strokes and HCM genetic subtypes, but we were underpowered for this analysis with few stroke events (data not shown). There have been several reports demonstrating that AF is a predictor of thromboembolic events in HCM patients, 34 and larger studies will be needed to demonstrate the associations between stroke and the genotype, particularly because anticoagulation may be important for prevention of thromboembolism in HCM patients 35 and is recommended in the current guidelines.
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CONCLUSIONS
We provide evidence of an association between rare variation in the MYH7 gene and AF in HCM patients. HCM patients with LP/P variation in the MYH7 gene may be at a higher risk of developing AF than those with variation in other sarcomeric genes and may benefit from closer surveillance for atrial arrhythmias. Studies that further unravel the link between MYH7 and AF may lead to interventions that could ultimately mitigate the rates of AF and its comorbidities in patients with HCM.
